NO174833C - Fremgangsmåte for fremstilling av et injiserbart preparat - Google Patents

Fremgangsmåte for fremstilling av et injiserbart preparat

Info

Publication number: NO174833C
Authority: NO; Norway
Prior art keywords: vesicles; preparation; fungal infections; systemic fungal; particles
Prior art date: 1986-08-21

Application number

NO873492A

Other languages

English (en)

Norwegian (no)

Other versions

NO873492D0 (no

NO174833B (no

NO873492L (no

Inventor

Jill Adler-Moore

Ronald Carl Gamble

Richard Thomas Proffitt

Original Assignee

Vestar Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-21

Filing date

1987-08-19

Publication date

1994-07-20

1987-08-19 Application filed by Vestar Inc filed Critical Vestar Inc

1987-08-19 Publication of NO873492D0 publication Critical patent/NO873492D0/no

1988-02-22 Publication of NO873492L publication Critical patent/NO873492L/no

1994-04-11 Publication of NO174833B publication Critical patent/NO174833B/no

1994-07-20 Publication of NO174833C publication Critical patent/NO174833C/no

Links

238000000034 method Methods 0.000 title abstract 2
230000000843 anti-fungal effect Effects 0.000 abstract 3
229940121375 antifungal agent Drugs 0.000 abstract 3
206010017533 Fungal infection Diseases 0.000 abstract 2
208000031888 Mycoses Diseases 0.000 abstract 2
230000003115 biocidal effect Effects 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
239000002245 particle Substances 0.000 abstract 2
150000004291 polyenes Chemical class 0.000 abstract 2
230000009885 systemic effect Effects 0.000 abstract 2
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
239000007983 Tris buffer Substances 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 1
229960003942 amphotericin b Drugs 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
229940088710 antibiotic agent Drugs 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
229960000988 nystatin Drugs 0.000 abstract 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 abstract 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
150000003904 phospholipids Chemical class 0.000 abstract 1
239000000243 solution Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Nanotechnology (AREA)
Dispersion Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Biophysics (AREA)
Crystallography & Structural Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO873492A 1986-08-21 1987-08-19 Fremgangsmåte for fremstilling av et injiserbart preparat NO174833C (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US89906486A	1986-08-21	1986-08-21

Publications (4)

Publication Number	Publication Date
NO873492D0 NO873492D0 (no)	1987-08-19
NO873492L NO873492L (no)	1988-02-22
NO174833B NO174833B (no)	1994-04-11
NO174833C true NO174833C (no)	1994-07-20

Family

ID=25410437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO873492A NO174833C (no)	1986-08-21	1987-08-19	Fremgangsmåte for fremstilling av et injiserbart preparat

Country Status (14)

Country	Link
US (1)	US5874104A (de)
EP (1)	EP0260811B1 (de)
JP (1)	JPH0615475B2 (de)
KR (1)	KR950013747B1 (de)
AT (1)	ATE66597T1 (de)
AU (1)	AU606880B2 (de)
CA (1)	CA1292184C (de)
DE (1)	DE3772498D1 (de)
DK (1)	DK168982B1 (de)
ES (1)	ES2051740T3 (de)
GR (1)	GR3002852T3 (de)
HK (1)	HK115393A (de)
IE (1)	IE60901B1 (de)
NO (1)	NO174833C (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2620028B2 (fr) *	1986-12-05	1994-02-25	Ire Celltarg Sa	Procede de preparation de microcristaux comportant a titre de substance active, notamment de l'amphotericine b, microcristaux obtenus et composition pharmaceutique en comprenant
CA1338736C (fr) *	1986-12-05	1996-11-26	Roger Baurain	Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
US4812312A (en) *	1987-03-03	1989-03-14	Board Of Regents Of The University Of Texas System	Liposome-incorporated nystatin
CA1338702C (en) *	1987-03-05	1996-11-12	Lawrence D. Mayer	High drug:lipid formulations of liposomal- antineoplastic agents
US5616334A (en) *	1987-03-05	1997-04-01	The Liposome Company, Inc.	Low toxicity drug-lipid systems
US6406713B1 (en)	1987-03-05	2002-06-18	The Liposome Company, Inc.	Methods of preparing low-toxicity drug-lipid complexes
US4999199A (en) *	1988-11-10	1991-03-12	Board Of Regents, The University Of Texas System	Pharmaceutical formulations: liposomes incorporating aromatic polyene antibiotics
EP0598116B1 (de) *	1989-11-27	1996-07-24	Nippon Shinyaku Company, Limited	Fettemulsion
EP0567559A1 (de) *	1991-01-14	1993-11-03	The United States Of America	Anti-hiv-aktivität von liposomalem nystatin und amphotericin-b
WO1993007884A1 (fr) *	1991-10-25	1993-04-29	Senju Pharmaceutical Co., Ltd.	Preparation externe de traitement de maladies hemorroidaires
JP2915296B2 (ja) *	1993-08-30	1999-07-05	宇野潤	抗真菌製剤
GB9519654D0 (en) *	1995-09-27	1995-11-29	Nycomed Imaging As	Stabilised phospholipid compositions
BR9707081A (pt)	1996-01-25	1999-05-25	Schering Ag	Soluções de injeção e infusão concentradas aperfeiçoadas para aplicação intravasal
GB9721901D0 (en) *	1997-10-16	1997-12-17	Univ Manchester	Particles
IL136342A0 (en) *	1997-12-01	2001-05-20	Yissum Res Dev Co	Formulation for topical treatment of skin infections
IT1301807B1 (it) *	1998-06-25	2000-07-07	Tiberio Bruzzese	Formulazioni farmaceutiche iniettabili di derivati della partricina.
US6613352B2 (en)	1999-04-13	2003-09-02	Universite De Montreal	Low-rigidity liposomal formulation
US6413537B1 (en)	2000-03-10	2002-07-02	Wisconsin Alumni Research Foundation	Nystatin formulation having reduced toxicity
JP4786041B2 (ja) *	2001-03-02	2011-10-05	丸善製薬株式会社	渋味、収斂味を低減する方法および渋味、収斂味低減ハス胚芽抽出物製剤
US7651689B2 (en) *	2002-11-15	2010-01-26	Albert Einstein College Of Medicine Of Yeshiva University	Methods of applying ionization radiation for therapy of infections
AU2006294644A1 (en) *	2005-09-27	2007-04-05	Amunix, Inc.	Proteinaceous pharmaceuticals and uses thereof
US7855279B2 (en) *	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
US20090099031A1 (en) *	2005-09-27	2009-04-16	Stemmer Willem P	Genetic package and uses thereof
US7846445B2 (en) *	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
US8067433B2 (en)	2005-11-09	2011-11-29	Zalicus Inc.	Methods, compositions, and kits for the treatment of ophthalmic disorders
CA2841386A1 (en)	2005-12-30	2007-07-12	Zensun (Shanghai) Science & Technology Limited	Extended release of neuregulin for improved cardiac function
CA2695374A1 (en) *	2007-08-15	2009-02-19	Amunix, Inc.	Compositions and methods for modifying properties of biologically active polypeptides
EP3246034A1 (de)	2008-03-06	2017-11-22	Anacor Pharmaceuticals, Inc.	Boronhaltige kleinmoleküle als entzündungshemmende wirkstoffe
DK3178835T3 (da)	2009-02-03	2019-06-24	Amunix Pharmaceuticals Inc	Forlængede rekombinante polypeptider og sammensætninger omfattende samme
WO2010144508A1 (en)	2009-06-08	2010-12-16	Amunix Operating Inc.	Glucose-regulating polypeptides and methods of making and using same
PE20121539A1 (es)	2009-06-08	2012-12-06	Amunix Operating Inc	Polipeptidos de la hormona de crecimiento y metodos de preparacion
WO2011006073A1 (en)	2009-07-10	2011-01-13	President And Fellows Of Harvard College	Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
CA2771999A1 (en)	2009-08-24	2011-03-10	Amunix Operating Inc.	Coagulation factor vii compositions and methods of making and using same
BRPI1003990B1 (pt) *	2009-10-16	2021-09-14	Lifecare Innovations Pvt. Ltd	Formulação para o tratamento de infecções fúngicas
BR112012009801A8 (pt)	2009-10-30	2016-08-30	Cns Therapeutics Inc	Polipeptídeo neurturina e variante de neurturina
JP6200648B2 (ja)	2009-12-18	2017-09-20	アケリオスセラピューティクス，インコーポレーテッド	三叉神経・自律神経性頭痛、片頭痛、および血管症状の治療および予防のための組成物
US8716478B2 (en)	2010-01-27	2014-05-06	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules
WO2012066896A1 (ja) *	2010-11-19	2012-05-24	Kato Junji	組合わせ医薬製剤
CN111548418A (zh)	2012-02-15	2020-08-18	比奥贝拉蒂治疗公司	因子viii组合物及其制备和使用方法
WO2013123457A1 (en)	2012-02-15	2013-08-22	Biogen Idec Ma Inc.	Recombinant factor viii proteins
US9156897B2 (en)	2012-06-08	2015-10-13	Alkermes, Inc.	Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
US10548953B2 (en)	2013-08-14	2020-02-04	Bioverativ Therapeutics Inc.	Factor VIII-XTEN fusions and uses thereof
EA201691111A1 (ru)	2014-01-10	2017-01-30	Байоджен Ма Инк.	Химерные белки фактора viii и их применение
CN107124869B (zh)	2014-03-25	2022-04-01	美国政府陆军部	包含含有单磷酰脂质a（mpla）的脂质体组合物和皂苷的无毒佐剂制剂
CN107614061A (zh)	2014-12-01	2018-01-19	阿科莱尔斯疗法公司	用于治疗与疼痛有关的偏头痛和病症方法和组合物
UA126016C2 (uk)	2015-08-03	2022-08-03	Біовератів Терапеутікс Інк.	Злитий білок фактора іх
US11021443B2 (en)	2015-08-03	2021-06-01	President And Fellows Of Harvard College	Charged ion channel blockers and methods for use
IL286493B (en)	2015-11-06	2022-07-01	Memorial Sloan Kettering Cancer Center	Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
WO2018035380A1 (en)	2016-08-17	2018-02-22	Solstice Biologics, Ltd.	Polynucleotide constructs
KR20190090827A (ko)	2016-12-02	2019-08-02	바이오버라티브 테라퓨틱스 인크.	키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
CN110582282A (zh)	2017-04-25	2019-12-17	佐剂技术公司	三萜皂苷类似物
US11597744B2 (en)	2017-06-30	2023-03-07	Sirius Therapeutics, Inc.	Chiral phosphoramidite auxiliaries and methods of their use
JP2020536946A (ja)	2017-10-16	2020-12-17	アジュバンス・テクノロジーズ・インコーポレーテッド	トリテルペンサポニン類似物
KR102914074B1 (ko)	2018-05-18	2026-01-16	바이오버라티브 테라퓨틱스 인크.	A형 혈우병의 치료 방법
US11377422B2 (en)	2019-03-11	2022-07-05	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
CA3129089A1 (en)	2019-03-11	2020-09-17	Bridget Mccarthy Cole	Ester substituted ion channel blockers and methods for use
US10828287B2 (en)	2019-03-11	2020-11-10	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
CN113811305A (zh)	2019-03-11	2021-12-17	诺西恩医疗公司	带电的离子通道阻滞剂及其使用方法
US10780083B1 (en)	2019-03-11	2020-09-22	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
WO2020227646A1 (en)	2019-05-09	2020-11-12	Apkarian Technologies Llc	Methods and compositions for treating pain
EP4021934A4 (de)	2019-08-30	2024-02-14	The Regents of the University of California	Screening-methoden von genfragment-überexpressionen und ihre verwendungen
AU2020379738A1 (en)	2019-11-05	2022-04-14	Adjuvance Technologies, Inc.	Varicella zoster
AU2020380118B2 (en)	2019-11-06	2026-06-11	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
CA3155568A1 (en)	2019-11-06	2021-05-14	Bridget Mccarthy Cole	Charged ion channel blockers and methods for use
US11332446B2 (en)	2020-03-11	2022-05-17	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
US12162851B2 (en)	2020-03-11	2024-12-10	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
PH12022553407A1 (en)	2020-06-25	2024-04-22	Amunix Pharmaceuticals Inc	Her-2 targeted bispecific compositions and methods for making and using the same
WO2022204267A1 (en)	2021-03-24	2022-09-29	Alkermes, Inc.	Upar antibodies and fusion proteins with the same
AU2023235562B2 (en)	2022-03-14	2026-07-30	Pfizer Inc.	Methods for producing an adjuvant
IL315719A (en)	2022-03-21	2024-11-01	Univ Illinois	Prosthetic assemblies of ion channels containing lipid-coated amphotericin B crystals
CN120513083A (zh)	2022-12-01	2025-08-19	辉瑞大药厂	肺炎链球菌缀合物疫苗制剂
TWI909678B (zh)	2023-09-13	2025-12-21	美商輝瑞股份有限公司	產製佐劑之方法
TW202602467A (zh)	2024-03-11	2026-01-16	美商輝瑞股份有限公司	包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
WO2026088120A1 (en)	2024-10-24	2026-04-30	Pfizer Inc.	Lipidated tlr7/8 modulators as adjuvants and uses thereof
US20260166136A1 (en)	2024-12-18	2026-06-18	Pfizer Inc.	Immunogenic compositions and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4310505A (en) *	1979-11-08	1982-01-12	California Institute Of Technology	Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4497791A (en) *	1983-02-10	1985-02-05	Vestar Research Incorporated	Method for labeling phagocytic cells
GB2135647A (en) *	1983-02-15	1984-09-05	Squibb & Sons Inc	Method of preparing liposomes and products produced thereby
PT78628B (en) *	1984-05-02	1986-06-18	Liposome Co Inc	Pharmaceutical composition with reduced toxicity
US4880635B1 (en) *	1984-08-08	1996-07-02	Liposome Company	Dehydrated liposomes
IE58659B1 (en) *	1984-10-22	1993-11-03	Vestar Inc	Use of a micellular particle composition encapsulating a chemotherapeutic agent for intravenous targeting to tumors
US4753788A (en) *	1985-01-31	1988-06-28	Vestar Research Inc.	Method for preparing small vesicles using microemulsification
US4766046A (en) *	1985-09-27	1988-08-23	Liposome Technology, Inc.	Stabilized liposome/amphotericin composition and method
US4812312A (en) *	1987-03-03	1989-03-14	Board Of Regents Of The University Of Texas System	Liposome-incorporated nystatin

1987
- 1987-08-11 IE IE214887A patent/IE60901B1/en not_active IP Right Cessation
- 1987-08-14 ES ES87307221T patent/ES2051740T3/es not_active Expired - Lifetime
- 1987-08-14 AT AT87307221T patent/ATE66597T1/de not_active IP Right Cessation
- 1987-08-14 DE DE8787307221T patent/DE3772498D1/de not_active Expired - Lifetime
- 1987-08-14 EP EP87307221A patent/EP0260811B1/de not_active Expired - Lifetime
- 1987-08-18 AU AU77160/87A patent/AU606880B2/en not_active Expired
- 1987-08-19 CA CA000544830A patent/CA1292184C/en not_active Expired - Lifetime
- 1987-08-19 NO NO873492A patent/NO174833C/no not_active IP Right Cessation
- 1987-08-20 KR KR1019870009101A patent/KR950013747B1/ko not_active Expired - Lifetime
- 1987-08-20 DK DK434187A patent/DK168982B1/da not_active IP Right Cessation
- 1987-08-21 JP JP62208049A patent/JPH0615475B2/ja not_active Expired - Fee Related
1991
- 1991-10-08 GR GR91401494T patent/GR3002852T3/el unknown
1993
- 1993-10-28 HK HK1153/93A patent/HK115393A/en not_active IP Right Cessation
1995
- 1995-06-06 US US08/467,864 patent/US5874104A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA1292184C (en)	1991-11-19
JPS6366123A (ja)	1988-03-24
NO873492D0 (no)	1987-08-19
EP0260811A3 (en)	1988-07-20
DK434187D0 (da)	1987-08-20
AU7716087A (en)	1988-02-25
ATE66597T1 (de)	1991-09-15
NO174833B (no)	1994-04-11
US5874104A (en)	1999-02-23
JPH0615475B2 (ja)	1994-03-02
DK434187A (da)	1988-02-22
GR3002852T3 (en)	1993-01-25
DE3772498D1 (de)	1991-10-02
DK168982B1 (da)	1994-07-25
IE872148L (en)	1988-02-21
IE60901B1 (en)	1994-08-24
NO873492L (no)	1988-02-22
KR950013747B1 (ko)	1995-11-15
KR880002531A (ko)	1988-05-09
HK115393A (en)	1993-11-05
ES2051740T3 (es)	1994-07-01
EP0260811B1 (de)	1991-08-28
AU606880B2 (en)	1991-02-21
EP0260811A2 (de)	1988-03-23

Legal Events

Date	Code	Title	Description
2007-08-27	MK1K	Patent expired

Publication	Publication Date	Title
AU606880B2 (en)	1991-02-21	Improved treatment of systematic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
AU587232B2 (en)	1989-08-10	Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles and methods for using same for tumor therapy
US6221385B1 (en)	2001-04-24	Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof
AU8141791A (en)	1991-11-07	Method for determining unentrapped ionizable bioactive agents in liposome preparations
CA2233961A1 (en)	1997-04-10	Stimulation of hair follicles
NO180147C (no)	1997-02-26	Fremgangsmåte for fremstilling av HDLC eller et liposom innbefattende et polyen-antisopp-antibiotikum og et lipid
EP0100910A3 (en)	1985-11-21	Lung surfactant
DK32388A (da)	1988-07-28	Phospholipid-baeremiddel for vand-uoploeselige aktive bestanddele
ATE86104T1 (de)	1993-03-15	Mehrstufen-einkapselungs/ladeverfahren zur herstellung von lipophile heilmittel enthaltenden liposomen.
Demel et al.	1966	Penetration of lipid monolayers by psychoactive drugs